首页 | 本学科首页   官方微博 | 高级检索  
     


MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised,open-label phase 2 study
Authors:Paolo A Ascierto  Dirk Schadendorf  Carola Berking  Sanjiv S Agarwala  Carla ML van Herpen  Paola Queirolo  Christian U Blank  Axel Hauschild  J Thaddeus Beck  Annie St-Pierre  Faiz Niazi  Simon Wandel  Malte Peters  Angela Zubel  Reinhard Dummer
Affiliation:1. National Tumor Institute, Foundation “G Pascale”, Naples, Italy;2. University Hospital Essen, Essen, Germany;3. Department of Dermatology and Allergology, University of Munich, Munich, Germany;4. St Luke''s University Hospital and Temple University, Bethlehem, PA, USA;5. Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands;6. San Martino Hospital-National Institute for Cancer Research, largo Rosanna Benzi, Genova, Italy;7. Netherlands Cancer Institute, Amsterdam, Netherlands;8. University Hospital Schleswig-Holstein, Department of Dermatology, Kiel, Germany;9. Highlands Oncology Group, Fayetteville, AR, USA;10. Novartis Pharma, Basel, Switzerland;11. Universitätsspital Zürich, Zürich, Switzerland
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号